According to Cushman & Wakefield of Massachusetts, Dicerna Pharmaceuticals has entered into a 37,186 s/f lease agreement for its new corporate headquarters at 87 CambridgePark Dr.
Cushman & Wakefield executive director Mark Winters, senior director David Townsend and senior director Juliette Reiter represented King Street Properties, the landlord. Dicerna Pharmaceuticals was represented by Roy Hirshland, president, and Mike Shreve, senior vice president, of T3 Advisors.
King Street Props. recently closed on the purchase of 87 CambridgePark Dr., a two-story, 63,809 s/f laboratory building previously owned and occupied by Pfizer.
"Dicerna's interest in relocating to 87 CambridgePark Drive, immediately after our purchase of the building, validates our investment in the West Cambridge market," said King Street Properties' Principal Stephen Lynch. "The quality of the asset, combined with strong market fundamentals, makes us very optimistic about the future of this building."
"Dicerna's lease gives 87 CambridgePark Drive a terrific anchor tenant and a very exciting life science company," said Winters. "There's strong demand for high quality laboratory space throughout Cambridge, and we believe that 87 CambridgePark Dr. is very well positioned to meet that demand."
Dicerna's chief business officer Jim Weissman said, "The goal in Dicerna's search for a new headquarters location was to identify an office and laboratory space that would enhance our open and collaborative corporate culture.. The scale and setting of 87 CambridgePark Dr. offers Dicerna an expanded footprint in the dynamic Cambridge biotech community that is very much consistent with who we are as a company."